Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11413225 | 0.88 | TSHR (0.53) | TSHRHTTGAAMEN1KMT2A | |
| SCHEMBL976467 | 0.88 | TSHR (0.68) | TSHRHTTGAAMEN1KMT2A | |
| SCHEMBL9409750 | 0.86 | ALDH1A1 (0.57) | TSHRHTTGAAMEN1KMT2A | |
| SCHEMBL1930296 | 0.86 | MEN1 (0.70) | TSHRHTTGAAMEN1KMT2A | |
| SCHEMBL11419174 | 0.85 | GPBAR1 (0.61) | TSHRHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL8408128 | 0.85 | ALDH1A1 (0.60) | TSHRHTTGAAMEN1KMT2A | |
| SCHEMBL5533585 | 0.84 | L3MBTL1 (0.69) | TSHRHTTGAAMEN1KMT2A | |
| SCHEMBL13501824 | 0.84 | KMT2A (0.69) | TSHRHTTGAAMEN1KMT2A | |
| SCHEMBL316093 | 0.83 | KMT2A (0.76) | TSHRHTTGAAMEN1KMT2A | |
| SCHEMBL27722453 | 0.83 | KMT2A (0.76) | TSHRHTTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2010-05-06 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-4124714-A | TRANQUILIZERS, SLEEP INDUCERS, MUSCLE RELAXANTS, NEUROLEPTICS, ANTIULCER AGENTS | SANDOZ, INC. (US) | 1978-11-07 | — | — | US | disclosed |
| US-4122182-A | TRANQUILIZERS, SLEEP INDUCERS, MUSCLE RELAXANTS, NEUROLEPTICS | SANDOZ, INC. (US) | 1978-10-24 | — | — | US | disclosed |
| US-4113727-A | Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones | SANDOZ, INC. (US) | 1978-09-12 | — | — | US | disclosed |
| US-4103013-A | TRANQUILIZERS, SLEEP INDUCERS | SANDOZ, INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4086421-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4064251-A | TRANQUILIZERS, SLEEP INDUCERS, MUSCLE RELAXANTS | SANDOZ, INC. (US) | 1977-12-20 | — | — | US | disclosed |
| US-4060533-A | ANTIALLERGY | SANDOZ, INC. (US) | 1977-11-29 | — | — | US | disclosed |
| US-4054653-A | TRANQUILIZERS, SLEEP INDUCERS, MUSCLE RELAXANTS | SANDOZ, INC. (US) | 1977-10-18 | — | — | US | disclosed |
| US-4049813-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | TSHR 4432/4885HTT 601/4885GAA 562/4885 |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | TSHR 2748/4885HTT 1843/4885GAA 602/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | TSHR 2565/4885HTT 2106/4885GAA 3034/4885 |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | TSHR 3110/4885HTT 2777/4885GAA 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.